Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05202366 · ClinicalTrials.gov registry record
An Open-label Study Evaluating the Effectiveness of CGB-400 Topical Gel for Fungal Infection
A clinical trial, sponsored by CAGE Bio.
- Completed
- Registry status
- 15
- Enrollment target
NCT05202366 is a clinical trial that has completed, run by CAGE Bio. The registered enrollment target is 15 participants.
The verdict
NCT05202366 has completed, sponsored by CAGE Bio.
- COMPLETED
- Registry status
- 15 participants
- Enrollment target
Study Summary
The goal of the current study is to evaluate the ability of CGB-400, a proprietary eutectic mixture of GRAS compounds, to clear the toenail fungal growth and improve the appearance of the fungus affected area(s). This is an open-label, single group POC study evaluating the effectiveness of CGB-400 Topical Gel for toenail fungal growth clearing. The study consists of a 12-week period with 5 clinic visits at the following timepoints: Baseline (Day 0), and Weeks 2, 6, and 12 and post-application follow-up at Week 24. The applications could be extended for an additional 12 weeks based on PI's observations. Approximately 15 subjects will be enrolled and subjected to application of CGB-400 Topical Gel. Subjects must be at least 18 years of age and will be selected by the concerned PI.
Interventions
- DRUG CGB-400 Topical Gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2022-02-08 |
| Est. Completion | 2024-08-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05202366
The ClinicalTrials.gov registry entry for NCT05202366 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CAGE Bio, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CGB-400 Topical Gel is the first listed.
NCT05202366 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05202366 about?
NCT05202366 is a clinical study titled "An Open-label Study Evaluating the Effectiveness of CGB-400 Topical Gel for Fungal Infection". The goal of the current study is to evaluate the ability of CGB-400, a proprietary eutectic mixture of GRAS compounds, to clear the toenail fungal growth and improve the appearance of the fungus affected area(s). This is an open-label, single group POC study evaluating the effectiveness of CGB-400 ...
What is the current status of trial NCT05202366?
This trial is currently completed. The enrollment target is 15 participants. The study started on 2022-02-08. Estimated completion is 2024-08-08.
What interventions are being tested in trial NCT05202366?
The interventions under investigation include: CGB-400 Topical Gel (DRUG).
Who is sponsoring clinical trial NCT05202366?
This trial is sponsored by CAGE Bio, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.